Sort   by:  
 Page size 
UnknownPersistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Not available
S-EPMC9281359 | biostudies-literature
UnknownImmunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
Not available
S-EPMC9212880 | biostudies-literature
UnknownPhase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin®).
Not available
S-EPMC10439197 | biostudies-literature
UnknownSafety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Not available
S-EPMC7825810 | biostudies-literature
UnknownSafety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Not available
S-EPMC8221739 | biostudies-literature
UnknownEfficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Not available
S-EPMC8584828 | biostudies-literature
Sort   by:  
 Page size